News

September 21, 2020September 21, 2020

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

News

Patient dosing has begun in Zion Pharma‘s Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive ... Read more

September 17, 2020September 17, 2020

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

News

TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose ... Read more

September 14, 2020September 14, 2020

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

News

The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte‘s immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, ... Read more

September 10, 2020September 10, 2020

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

News

Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free ... Read more

September 3, 2020September 3, 2020

FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) is reviewing a new drug application from Athenex seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic ... Read more

August 31, 2020August 31, 2020

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

News

The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer ... Read more

August 27, 2020August 27, 2020

Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial

News

Tecentriq (atezolizumab) combined with chemotherapy failed to meet its primary endpoint of progression-free survival — the length of time during and after therapy in which the patient’s disease does not ... Read more

August 24, 2020August 24, 2020

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

News

The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor ... Read more

August 17, 2020August 17, 2020

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

News

The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who ... Read more

August 10, 2020August 27, 2020

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

News

The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment of patients with different forms ... Read more

Pin It on Pinterest